Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALD-102
- Development stage
- Unknown
- Lead developer
- Alys Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
ALD-102 is an investigational small interfering RNA (siRNA) therapy developed by Aldena Therapeutics (now part of Alys Pharmaceuticals) for the treatment of alopecia areata. It is formulated as an intradermal injectable solution designed to provide local and selective modulation of inflammation in the skin by targeting Janus kinase 1 (JAK1). JAK1 is a key driver of the inflammatory response that leads to hair follicle destruction in alopecia areata. By silencing JAK1 expression locally in the scalp, ALD-102 aims to restore hair growth while minimizing the systemic side effects often associated with oral JAK inhibitors. The therapy is currently undergoing Phase 1/2 clinical evaluation to assess its safety, pharmacokinetics, and preliminary efficacy in adults with alopecia areata.
- Other names
- ALD-102 SolutionALD102 SolutionALD 102 Solution
02
Targets
Beyond the preview
Go deeper on ALD-102.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALD-102.